No Prescription |
 |
 | ||
|
Rhinocort AqNasal Spray Rhinocort Aqua |
|
| ||
No Prescription » Prescription Drugs 14 » Rhinocort AqNasal Spray Rhinocort Aqua Budesonide is used to prevent and treat seasonal and year-round allergy symptoms (such as stuffy/runny nose itchy eyes/nose/throat sneezing). Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) in the nasal passages. Buy Rhinocort AqNasal Spray Rhinocort Aqua and other Prescription Drugs 14 products online at Medstore. Buy Online at Medstore - Click Here!
About Rhinocort AqNasal Spray Rhinocort Aqua: Product Type: Prescription Drugs 14 Rhinocort Aq.Nasal Spray ( Rhinocort Aqua Generic Budesonide Liquid Spray ) Rhinocort Aq.Nasal Spray (Rhinocort Aqua Generic Budesonide Liquid Spray) Rhinocort Aqua Generic Budesonide Liquid Spray 64mcg/Dose Rhinocort Aqua Generic Budesonide Liquid Spray Rhinocort Aq.Nasal Spray
View more Prescription Drugs 14 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
